All infertile women were treated with IVF‐ET from June 2017 to November 2017 in the Reproductive Medical Center of The First Affiliated Hospital of Nanjing Medical University. Our experimental scheme was approved by the Ethics Committee of the First Affiliated Hospital of Nanjing Medical University (Ethics No. 81370764). All the research participants signed the informed consent of the patients. Patients who participated in the study received long‐term regimen therapy. The diagnostic criteria of OHSS were borrowed from Golan criteria. 16 For the OHSS patients, the inclusion criteria were as follows: serum AMH > 5 ng/mL, serum E2 > 3500 pg/mL on HCG day and oocytes > 20. The controls were diagnosed with fallopian tubal diseases via laparoscopy and hysteroscopy, or exhibited male factor infertility. Women suffering from malignancy, benign ovarian cyst including endometrioma, allergic diseases; pelvic inflammation, known chronic, systemic, metabolic, or endocrine disease excluding polycystic ovarian syndrome, were excluded from this study.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.